Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

UNCOVERED: Hznp - Caught on Camera

3 Biotech Stocks Beating BioMarin Pharmaceutical (BMRN)

Breakthrough developments, the use of advanced technologies, and rising investments in R&D are some of the factors driving the growth of the biotech industry. Although BioMarin Pharmaceutical (BMRN) showcases strong growth prospects, investors could consider buying even better biotech stocks Amgen (AMGN), Jazz Pharmaceuticals (JAZZ), and Vertex Pharmaceuticals (VRTX). Read…

3 Pharma Stocks With Potential to Outperform Pfizer Inc. (PFE) in October

3 Pharma Stocks With Potential to Outperform Pfizer Inc. (PFE) in October

Pfizer (PFE) is grappling with financial difficulties and declining performance. Yet, with growing pharmaceutical demand and industry advancements, robust pharma stocks Zoetis (ZTS), Horizon Therapeutics (HZNP), and Novartis (NVS) appear as more promising buys this month. Read on.

3 Pharma Stocks Surpassing Johnson & Johnson (JNJ)

3 Pharma Stocks Surpassing Johnson & Johnson (JNJ)

The pharmaceutical sector is anticipated to thrive as demand grows and technology advances. While Johnson & Johnson (JNJ) receives much attention from investors, I believe Horizon Therapeutics Public Limited (HZNP), Dr. Reddy’s Laboratories (RDY), and Novartis (NVS) are better investments right now. Read on.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

3 Pharma Stocks for Value Investors

The aging global population and the growing demand for drugs and therapies to treat chronic diseases are boosting the long-term prospects of the pharmaceutical industry. Amid this backdrop, value investors could consider buying fundamentally strong pharma stocks GSK plc (GSK), Horizon Therapeutics (HZNP), and Neurocrine Biosciences (NBIX), as they are…

Stock Market Sell-Off: 4 Bargain Stocks Begging to Be Bought

The stock market has experienced a sell-off of late due to investor concerns about the Fed’s aggressive interest rate increases to tame inflation and a prospective economic contraction. Nevertheless, the sell-off has created opportunities for investors to buy quality stocks at bargain prices. We think Horizon Therapeutics (HZNP), TDK (TTDKY),…

Horizon Therapeutics: Q1 Earnings Insights

Horizon Therapeutics (NASDAQ:HZNP) reported its Q1 earnings results on Wednesday, May 4, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Horizon Therapeutics' Inebilizumab Scores European Approval For Spinal Cord Inflammation

The European Commission has approved Horizon Therapeutics plc's (NASDAQ:HZNP) Uplizna (inebilizumab) as monotherapy for neuromyelitis optica spectrum disorder (NMOSD) who are anti-aquaporin-4 immunoglobulin G seropositive (AQP4-IgG+). NMOSD is an autoimmune disease that attacks the optic nerve, spinal cord, brain, and brain stem. In the N-MOmentum pivotal clinical trial, Uplizna demonstrated a significant reduction…

inkl

Read news from The Economist, FT, and more,
with one subscription

Will Investors Notice Exciting Sign On Horizon Therapeutics's Chart?

Will Investors Notice Exciting Sign On Horizon Therapeutics's Chart?

If history is any guide, there may be good fortune ahead for shares of Horizon Therapeutics (NASDAQ:HZNP). A so-called "golden cross" has formed on its chart and, not surprisingly, this could be bullish for the stock.

Eton Pharmaceuticals Names James Gruber Finance Chief

Eton Pharmaceuticals Names James Gruber Finance Chief

Eton Pharmaceuticals Inc (NASDAQ:ETON) has appointed James Gruber as Chief Financial Officer effective immediately. He succeeds Wilson Troutman, who is retiring. Mr. Troutman will remain with the company through May to ensure a smooth transition. Mr. Gruber, most recently, was the U.S. Controller at Horizon Therapeutics (NASDAQ:HZNP) for seven years, where he oversaw…

Horizon Therapeutics Earnings Perspective: Return On Capital Employed

Horizon Therapeutics Earnings Perspective: Return On Capital Employed

Pulled from Benzinga Pro data, Horizon Therapeutics (NASDAQ:HZNP) posted Q4 earnings of $173.18 million, an increase from Q3 of 46.97%. Sales dropped to $1.01 billion, a 2.22% decrease between quarters.

Horizon Therapeutics' Q4 Earnings Beat Expectation As Tepezza, Krystexxa Boost Sales

Horizon Therapeutics' Q4 Earnings Beat Expectation As Tepezza, Krystexxa Boost Sales

Horizon Therapeutics plc's (NASDAQ:HZNP) Q4 sales increased 36% Y/Y to $1.014 billion, beating the consensus of $995.87 million. The adjusted gross profit declined slightly from 87.1% to 86.5%, with an adjusted EBITDA of $416.0 million, including $36.2 million of upfront and milestone payments primarily related to the collaboration agreement with Alpine. The…

Horizon Therapeutics: Q4 Earnings Insights

Horizon Therapeutics: Q4 Earnings Insights

Horizon Therapeutics (NASDAQ:HZNP) reported its Q4 earnings results on Tuesday, March 1, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

3 Large-Cap Healthcare Stocks with More Than 40% Upside, According to Wall Street

3 Large-Cap Healthcare Stocks with More Than 40% Upside, According to Wall Street

The healthcare industry is growing rapidly on increasing demand and continuing advancements in therapies. Furthermore, this year is expected to be a transformative one for the healthcare sector, with a more robust transition to digital health. Given the industry's growth potential, Wall Street analysts see more than 40% potential upside…

Horizon Therapeutics' Uplinza Reduces Severity of Attacks Associated Spinal Cord Inflammation

Horizon Therapeutics' Uplinza Reduces Severity of Attacks Associated Spinal Cord Inflammation

Horizon Therapeutics plc (NASDAQ: HZNP) shared results from a new analysis showing treatment with Uplinza

Get all your
news in one place.

100's of premium titles.
One news app.

Death Cross Looms Over Horizon Therapeutics Investors

If history is any guide, there may be trouble ahead for shares of Horizon Therapeutics (NASDAQ:HZNP). A so-called "death cross" has formed on its chart and, not surprisingly, this could be bearish for the stock.

1

People

Dipanjan BanchurSince

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

European Commission

Abbott Laboratories

Medical Pharmaceuticals

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Autoimmune Disease

Places

363,376 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play